Results 161 to 170 of about 1,825 (197)
Some of the next articles are maybe not open access.
Clinical Pharmacokinetics of Lornoxicam
Clinical Pharmacokinetics, 1998Lornoxican (chlorotenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours). Lornoxicam is eliminated following biotransformation to 5'-hydroxy-lornoxicam, which does not undergo enterohepatic recirculation.
N M, Skjodt, N M, Davies
openaire +2 more sources
European Journal of Inorganic Chemistry, 2003
AbstractThe synthesis and spectral characterisation of novel organotin complexes [SnMe2(lorn)] (1) and [SnBu2(lorn)] (2) of the potent and widely used anti‐inflammatory drug lornoxicam, H2lorn, are reported. Crystal structure determinations of complexes1 and 2 showed that the ligand is doubly deprotonated at the oxygen and amide nitrogen atoms and is ...
Angeliki Galani +3 more
openaire +1 more source
AbstractThe synthesis and spectral characterisation of novel organotin complexes [SnMe2(lorn)] (1) and [SnBu2(lorn)] (2) of the potent and widely used anti‐inflammatory drug lornoxicam, H2lorn, are reported. Crystal structure determinations of complexes1 and 2 showed that the ligand is doubly deprotonated at the oxygen and amide nitrogen atoms and is ...
Angeliki Galani +3 more
openaire +1 more source
Drugs, 1996
Lornoxicam (chlortenoxicam), a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties, is available in oral and parenteral formulations. It is distinguished from established oxicams by a relatively short elimination half-life (3 to 5 hours), which may be advantageous from a ...
J A, Balfour, A, Fitton, L B, Barradell
openaire +2 more sources
Lornoxicam (chlortenoxicam), a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties, is available in oral and parenteral formulations. It is distinguished from established oxicams by a relatively short elimination half-life (3 to 5 hours), which may be advantageous from a ...
J A, Balfour, A, Fitton, L B, Barradell
openaire +2 more sources
Lornoxicam in clinical practice.
Postgraduate medical journal, 1991Three studies reported here have confirmed that lornoxicam is effective in osteoarthritis and the ideal dose appears to be 12 mg daily. Overall, lornoxicam appears to be a useful drug in the treatment of both osteo- and rheumatoid arthritis, from the data presently available.
H, Berry, S, Ollier
openaire +1 more source
Pharmacokinetics of lornoxicam in man.
Postgraduate medical journal, 1991Clinical phase I pharmacokinetic studies with lornoxicam were performed with the 4 mg dose of lornoxicam. Lornoxicam was administered as an aqueous solution both orally and intravenously to young, healthy, male volunteers. The total excretion of lornoxicam via urine and faeces after oral administration was determined by administering 14C-labelled ...
G, Hitzenberger +3 more
openaire +1 more source
Severe gastrointestinal bleeding secondary to lornoxicam in the dog
Schweizer Archiv fur Tierheilkunde, 2011Six dogs with lornoxicam induced severe gastrointestinal bleeding are described. The ingested dose ranged between 0.5 - 5.1 mg/kg BW (median 0.63 mg/kg BW). The severity of the bloodloss anemia was moderate to severe with PCV values ranging between 12 - 27 % (median 16 %) and serum albumin concentrations between 12 - 22 g/l (median 16 g/l). One dog had
Kook, Peter H, Reusch, Claudia E
openaire +2 more sources
Antithrombotic potential of lornoxicam and possible mechanistic pathways
The Journal of Pharmacology and Experimental TherapeuticsLornoxicam is traditionally used as an anti-inflammatory and analgesic drug. Recent studies suggest that nonsteroidal anti-inflammatory drugs can influence platelet and coagulation pathways. However, the antithrombotic and cardiopulmonary protective potential of lornoxicam remains unexplored.
Waseem, Khalid +2 more
openaire +2 more sources
Clinical pharmacokinetic studies with lornoxicam.
Postgraduate medical journal, 1991Pharmacokinetic data from several studies in young and elderly human subjects are reviewed. Lornoxicam appears to be extensively metabolized and no unchanged drug has been found in the urine. It has a relatively short elimination half-life (about 4 hours), and no significant differences in pharmacokinetic data have been found between young and elderly ...
P, Turner, A, Johnston
openaire +1 more source